| abstract |
The present invention relates to a transdermal drug delivery device comprising:a transdermal adhesive composition comprising:an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; andat least one pharmaceutically active compound which is susceptible to oxidative degradation; wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive;a backing sheet coated with the transdermal adhesive composition, wherein the transdermal adhesive composition coating covers at least a portion of a major surface of the backing sheet wherein any free radical initiator, if present in the adhesive, is present at a level of less than 20 ppm, based upon the total weight of the adhesive; andwherein less than 0.1% of antioxidant is present in the transdermal adhesive composition. |